ProxyBio, LLC
ProxyBio’s organoid platform allows for the high-throughput feature-rich investigation of physiologically relevant systems and translation of results through artificial intelligence for drug discovery or personalized medicine.
The Problem
Current in vitro evaluation of therapeutic agents is restricted by either monoculture of cells or by missing the 3D-characteristics of more sophisticated models. The former causes a highly artificial environment that eliminates the inter-cellular communication. The latter poses challenges for the high-throughput testing. Physiologically relevant models are needed for either the pre-clinical selection and optimization of novel drug candidates or selecting personalized treatments for patients.
The Solution
The offered technology is built on organoids, 3D-dimensional communities of cells, which have gained increasing interest for drug discovery and diagnostic purposes. It enables the fast development and miniaturization of organoids from biopsies and their high-throughput imaging at the individual cell level under a variety of perturbations, collecting hundreds of features from thousands of cells, creating an information-rich test outcome not possible before. This high-density information is translated through proprietary AI models into predictive and actionable outputs.
The Opportunity
The commercialization of the technology may start from a service model with long-term collaborations around specific cell and organoid models. It will allow the establishment of proprietary drug discovery programs starting from more complex cell systems that reflect interactions in communities of various cell types reflecting responses to perturbances with high resolution and content, adding additional value and markets.
Status
The organoid preparation and imaging platform have been established. Collected data have been used to build AI-models for correlation to basic biological pathways. Currently, an extended validation program for the translation of results into a predictive model for clinical observations is ongoing. The next steps are the translation of the results for diagnostics and compound optimization.
Meet the Team
Curtis Thorne PhD
College Of Medicine - Tucson
Kelvin Pond PhD
College Of Medicine - Tucson
Peter Nestler PhD
Tech Launch Arizona
Al Kassam MBA
Tech Launch Arizona
Contact us today.
Check out more Pharma startups.
View All Startups & Inventions
Many cancer drugs suffer from severe adverse effects due to acute high exposure and inadequate distribution to tumors. This technology provides a vehicle for the preferred delivery of existing and approved drugs to tumor environments and local release of the active agent, thereby focusing exposure to tissues in need and reducing unwanted side effects.
Senfina offers in vivo whole life drug discovery services for aging and age-related diseases based on a multi-feature high-throughput imaging platform using C. elegans as a model organism.
Precision anti-infective technology focused on a microbiome sparing strategy. We target Clostridioides difficile infection (CDI), an antibiotic-associated infectious diarrheal disease, through oral delivery of a targeted Antisense Oligonucleotide.
Safe Lactobacillus-based synthetic biologic as a colonization resistance agent of, and oral vaccine for, Clostridioides difficile infection (CDI).
